AVVH...DD...Superior Lead Product. Tests in Germany have proven that the NEUROSKIN product to be effective on 995 out of 1000 people (99.5%). The tests indicated and proved NEUROSKIN did not cause any side effects. Unlike many competitors, NEUROSKIN does not contain cortisone, antibiotics, alcohol, steroids or other unnatural ingredients or additives. The formula is non-greasy and odorless, does not stain clothing, and is easy to use.
Huge Market Potential. The United States alone has an estimated market size of 40 million skin disease sufferers and a potential market spending of US $4 Billion. There are 7 million people living in the United States that are affected by some form of psoriasis. Approximately two hundred and fifty thousand new cases are reported each year.
Increased Sales Channels. Avvaa World Health Care is preparing to launch its Neuroskin® Psoriasis Relief product via a nationwide media blitz. Among other things, The NEUROSKIN Psoriasis Relief will be introduced throughout the United States by a 120 second direct response infomercial and will start airing in [edit]August 2009, and by the fall of 2009 avVaa’s Sales & Marketing Division will introduce NEUROSKIN Psoriasis Relief on a Regional basis as part of mainstream OTC products to major drug stores across the United States.
